文献速递膀胱癌与上尿路尿路上皮癌

根治性膀胱切除术中预防性尿道切除术对肿瘤学结局的影响

Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes?
PubMed 文献 · BJU Int · 2025-12-23

该单中心回顾性研究纳入1996至2022年间581例接受根治性膀胱切除术的男性患者,经倾向性评分匹配后各166例接受或未接受预防性尿道切除术。预防性尿道切除术组10年总生存率显著更高(47.3% vs 27.5%,P=0.002),但癌症特异性生存和无复发生存无显著差异,10年尿道无复发生存在匹配后差异亦无统计学意义。

要点

  • 预防性尿道切除术与10年总生存率改善显著相关(47.3% vs 27.5%,P=0.002)。
  • 癌症特异性生存和无复发生存两组间无显著差异。
  • 匹配后尿道无复发生存的优势不再显著(98.2% vs 95.9%)。

核心结论

  • 预防性尿道切除术组在2年、5年和10年随访时总生存率显著优于未行该手术组。
  • 癌症特异性生存和无复发生存两组间无显著差异。
  • 预防性尿道切除术与10年尿道复发风险降低相关,但校正混杂因素后该优势不再显著。

研究设计与样本

  • 单中心三级转诊中心1996至2022年间1028例根治性膀胱切除术患者的回顾性研究。
  • 纳入581例接受不可控或可控性皮肤尿流改道的男性患者。
  • 经倾向性评分匹配后形成332例队列,预防性尿道切除术组与未行该手术组各166例。

主要发现

  • 预防性尿道切除术组10年总生存率为47.3%,未行该手术组为27.5%(P=0.002)。
  • 匹配前10年尿道无复发生存率预防性尿道切除术组为97.9%,未行该手术组为90.9%(P=0.05)。
  • 匹配后10年尿道无复发生存率分别为98.2%和95.9%,差异无统计学意义。
  • 总生存的独立预测因素包括年龄≥80岁(P=0.013)、Charlson合并症指数评分≥3(P=0.002)、病理N分期≥N1(P<0.001)、手术切缘阳性(P<0.001)和行预防性尿道切除术(P=0.015)。

临床怎么用

  • 预防性尿道切除术可能对特定患者有益,尤其是前列腺尿道受累者。
  • 需权衡总生存获益与尿道复发风险降低不显著之间的平衡。

局限性

  • 回顾性单中心设计可能存在选择偏倚。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the oncological impact of prophylactic urethrectomy (PU) on recurrence, metastasis, and survival outcomes, as PU was historically performed alongside radical cystectomy (RC) in men but has become rare with the increasing use of orthotopic neobladder substitution and uncertain survival benefits. PATIENTS AND METHODS: A total of 1028 patients underwent RC at a single tertiary referral center between 1996 and 2022. Among them, 581 males who received either incontinent urinary diversion or continent cutaneous diversion were identified. A propensity score matching was performed to minimise selection bias, yielding a cohort of 332 patients, of whom 166 underwent PU and 166 did not. Kaplan-Meier survival analysis was conducted to evaluate recurrence-free survival (RFS), urethral recurrence-free survival (URFS), cancer-specific survival (CSS), and overall survival (OS) at multiple time points postoperatively. Differences in survival outcomes between the two groups were assessed using the log-rank test. RESULTS: A trend toward improved CSS was observed in the PU group; however, the difference was not significant, and no notable variation was found in RFS. At 10 years, URFS was higher in the PU group (97.9% vs 90.9%, P = 0.05), but after matching, this difference (98.2% vs 95.9%) was no longer significant. A significant improvement in OS was observed among patients who underwent PU, with a 10-year survival rate of 47.3% compared to 27.5% in those who did not receive the procedure (P = 0.002). Independent predictors of OS included age ≥80 years (P = 0.013), Charlson Comorbidity Index score ≥3 (P = 0.002), pathological N-stage ≥N1 (P < 0.001), positive surgical margins (P < 0.001), and performing PU (P = 0.015). CONCLUSIONS: Patients undergoing PU had significantly improved OS at 2-, 5-, and 10-year follow-up compared to those who did not. No significant differences were found in CSS and RFS. While PU was associated with a reduced risk of urethral recurrence at 10 years, this advantage was no longer significant after adjusting for confounders. The procedure may be most beneficial for select patients, particularly those with prostatic urethral involvement.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Mennes J, Akand M, Benijts R, et al. Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes? BJU Int. 2025. PMID: 41432584. doi:10.1111/bju.70096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。